What question did this study set out to answer?

Evaluate the effectiveness of the fatty liver index (FLI) in diagnosing hepatic steatosis (HS) and its relationship with fibrosis in people living with HIV.

April 15, 2026

Diagnostic Performance of Fatty Liver Index for Hepatic Steatosis and its Association With Fibrosis in People Living With HIV

Key Points

Evaluate the effectiveness of the fatty liver index (FLI) in diagnosing hepatic steatosis (HS) and its relationship with fibrosis in people living with HIV.
Analyzed the diagnostic performance of the fatty liver index (FLI) against controlled attenuation parameter (CAP) measurements.
Assessed concordance of FLI results with CAP in people living with HIV.
Investigated the performance of FLI specifically in lean individuals within the population.
FLI missed nearly half of the hepatic steatosis cases defined by CAP.
Substantial limitations were found in screening for HS, especially in lean individuals.
FLI is not reliable as a standalone tool for diagnosing hepatic steatosis.

Abstract

FLI demonstrates substantial limitations as a screening tool for HS in people living with HIV, missing nearly half of CAP-defined cases. The poor concordance with CAP and particularly weak performance in lean individuals-who represent a significant proportion of PWH-indicate that FLI cannot reliably identify HS in this population and should not be used as a standalone diagnostic tool.

Bookmark

Cite This Study

Cordie et al. (Mon,) studied this question.

synapsesocial.com/papers/69df2b2ce4eeef8a2a6b0197 https://doi.org/https://doi.org/10.1097/qai.0000000000003809

Bookmark